HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFRA Chair Looks Forward To Post-COVID-19 ‘Revival Of Reason’

Executive Summary

IFRA’s new chairman Hans Holger Gliewe says one possible positive outcome of the COVID-19 pandemic could be that consumers go on putting a premium on scientific expertise after months of reliance on health experts’ advice. The public’s changed perspective could help drive science-based regulatory decision making, a caused long championed by the fragrance and beauty product industries.

You may also be interested in...



With ‘Commercial Health,’ US Essential Business Guidance Expands Well Beyond Supplements

DHS agency’s latest guidance for state, local governments to define essential businesses during pandemic includes “commercial health” and personal care products. Natural Products Association says supplement market is “surging” on its efforts to include the segment in earlier DHS guidance.

2020 US Beauty May Be Headed For Record Declines, But There Are COVID-19 Opportunities

Kline & Company’s worst-case scenario – which it says is looking more and more likely – has the US cosmetics and personal-care market declining by as much as 8.1% in 2020. However, Kline, Mintel and other market intelligence firms say there are opportunities available to companies struggling to weather the COVID-19 storm.

US And Trading Neighbors Advocate Risk-Based, Science-Backed Cosmetics Regs

As European industry’s concerns grow about “politicization” of regulatory programs, the United States-Mexico-Canada Agreement’s cosmetics annex directs regulatory authorities pursuing new rules to give due consideration to scientific and technical guidance documents developed through international collaboration.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel